Eurofins Scientific SE (ERFSF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ERFSF steht fuer Eurofins Scientific SE, ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 43/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 18. März 2026Eurofins Scientific SE (ERFSF) Gesundheitswesen & Pipeline-Uebersicht
Eurofins Scientific SE is a global leader in analytical testing and laboratory services, providing a comprehensive suite of solutions across diverse sectors, including food, environment, pharmaceuticals, and consumer products. The company's extensive network and scientific expertise position it as a key player in ensuring safety and quality standards worldwide.
Investmentthese
Eurofins Scientific SE presents a compelling investment case due to its diversified service offerings and global presence in the analytical testing market. With a market capitalization of $12.91 billion, the company benefits from a stable revenue stream driven by regulatory requirements and increasing consumer demand for safety and quality. A gross margin of 22.5% and an ROE of 9.5% indicate solid profitability. Ongoing: The company's strategic acquisitions and expansion into high-growth areas such as biopharma and environmental testing are expected to drive future revenue growth. However, a debt-to-equity ratio of 96.84 and a beta of 0.94 suggest moderate financial risk and market sensitivity.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $12.91 billion reflects its significant presence in the analytical testing market.
- Profit margin of 6.5% indicates moderate profitability within the competitive diagnostics and research sector.
- Gross margin of 22.5% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Return on Equity (ROE) of 9.5% suggests efficient utilization of shareholder equity to generate profits.
- Debt-to-Equity ratio of 96.84 indicates a relatively high level of financial leverage.
Wettbewerber & Vergleichsunternehmen
Staerken
- Global presence with an extensive network of laboratories.
- Diversified service offerings across multiple industries.
- Strong reputation for scientific expertise and quality.
- Proven track record of strategic acquisitions and growth.
Schwaechen
- High debt-to-equity ratio.
- Exposure to regulatory changes and compliance risks.
- Dependence on acquisitions for growth.
- Potential for price competition in certain markets.
Katalysatoren
- Upcoming: Expansion of biopharma testing services to capitalize on the growing biopharmaceutical industry.
- Ongoing: Strategic acquisitions to expand service offerings and geographic reach.
- Ongoing: Increasing focus on environmental testing to meet growing demand for environmental monitoring.
- Ongoing: Leveraging technological advancements to improve efficiency and accuracy of testing processes.
Risiken
- Potential: High debt-to-equity ratio could limit financial flexibility.
- Potential: Changes in regulatory requirements and compliance standards could increase costs.
- Potential: Economic downturns could reduce spending on testing services.
- Ongoing: Intense competition from other testing laboratories could put pressure on pricing.
- Potential: Product liability claims and recalls could damage reputation and financial performance.
Wachstumschancen
- Expansion in Biopharma Testing: The biopharmaceutical industry is experiencing rapid growth, driven by the development of novel therapies and increasing regulatory scrutiny. Eurofins can capitalize on this trend by expanding its biopharma testing services, including drug discovery, clinical trials, and quality control. The global biopharmaceutical testing market is projected to reach $120 billion by 2027, offering significant growth potential for Eurofins. Timeline: Ongoing.
- Increasing Focus on Environmental Testing: Growing concerns about environmental pollution and climate change are driving demand for environmental testing services. Eurofins can leverage its expertise in water, air, and soil testing to capture a larger share of this market. The global environmental testing market is expected to reach $35 billion by 2026, presenting a substantial opportunity for Eurofins. Timeline: Ongoing.
- Growth in Food Safety Testing: With increasing consumer awareness of food safety and stricter regulations, the demand for food testing services is growing. Eurofins can expand its food testing capabilities, including allergen testing, GMO testing, and pesticide residue testing, to meet this demand. The global food safety testing market is projected to reach $22 billion by 2025, providing a significant growth avenue for Eurofins. Timeline: Ongoing.
- Penetration of Emerging Markets: Emerging markets, such as China, India, and Brazil, are experiencing rapid economic growth and increasing demand for testing and analytical services. Eurofins can expand its presence in these markets through strategic acquisitions and partnerships. The growth in these regions offers substantial opportunities for Eurofins to increase its global market share. Timeline: Ongoing.
- Strategic Acquisitions: Eurofins has a history of growth through strategic acquisitions. By acquiring smaller testing laboratories and specialized service providers, Eurofins can expand its service offerings, geographic reach, and customer base. This strategy allows Eurofins to quickly enter new markets and gain access to specialized expertise. Timeline: Ongoing.
Chancen
- Expansion in high-growth areas such as biopharma and environmental testing.
- Penetration of emerging markets with increasing demand for testing services.
- Leveraging technological advancements to improve efficiency and accuracy.
- Increasing outsourcing of testing services by large corporations.
Risiken
- Economic downturns and reduced spending on testing services.
- Increased competition from other testing laboratories.
- Changes in regulatory requirements and compliance standards.
- Potential for product liability claims and recalls.
Wettbewerbsvorteile
- Extensive network of laboratories across the globe.
- Wide range of testing services across various industries.
- Strong reputation for scientific excellence and customer service.
- Strategic acquisitions to expand service offerings and geographic reach.
Ueber ERFSF
Founded in 1987 and headquartered in Luxembourg, Eurofins Scientific SE has grown from a small food testing laboratory to a global leader in analytical testing and laboratory services. The company's initial focus on food authenticity testing has expanded significantly to encompass a wide range of industries, including pharmaceuticals, environmental science, agriculture, and consumer products. Eurofins provides services such as agroscience, biopharma, clinical diagnostics, and consumer product testing. Its offerings include biological assessment, consumer and human safety testing, product chemistry, regulatory consultancy, and seed services. The company also provides assurance services, including sustainability audits, certification, quality inspection, and food and dietary supplement labeling. Eurofins operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste. It also offers specialized testing services such as forensic, genomic, maritime, materials and engineering, and sensory and consumer services. Eurofins' commitment to scientific excellence and customer service has driven its growth, making it a trusted partner for businesses seeking to ensure the safety, quality, and compliance of their products and processes.
Was das Unternehmen tut
- Provides analytical testing services for food, environment, pharmaceutical, and consumer products.
- Offers laboratory services, including water, air, and soil testing.
- Conducts biological assessments and product chemistry testing.
- Provides regulatory consultancy and seed services.
- Offers sustainability audits, certification, and quality inspection services.
- Provides clinical diagnostics and biopharma testing services.
- Offers forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services.
Geschaeftsmodell
- Generates revenue by providing analytical testing and laboratory services to various industries.
- Offers a wide range of testing services, including food, environment, pharmaceutical, and consumer products.
- Operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste.
- Acquires smaller testing laboratories and specialized service providers to expand its service offerings and geographic reach.
Branchenkontext
Eurofins Scientific SE operates in the diagnostics and research industry, which is characterized by increasing demand for testing and analytical services driven by stringent regulatory requirements and growing consumer awareness of safety and quality. The global market for testing, inspection, and certification is projected to reach $250 billion by 2028, growing at a CAGR of 4.5%. Eurofins competes with companies such as SGS SA, Intertek Group, and Bureau Veritas, offering a wide range of testing services across various sectors. The industry is also influenced by technological advancements, such as automation and data analytics, which are improving the efficiency and accuracy of testing processes.
Wichtige Kunden
- Food manufacturers and processors
- Pharmaceutical companies
- Environmental agencies and organizations
- Consumer product manufacturers
- Government agencies
Finanzdaten
Chart & Info
Eurofins Scientific SE (ERFSF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 24. März 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· 4. Dez. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ERFSF.
Kursziele
Wall-Street-Kurszielanalyse fuer ERFSF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ERFSF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
ERFSF OTC-Marktinformationen
ERFSF wird auf der OTC Other-Marktstufe der OTC Markets gehandelt.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
ERFSF Healthcare Aktien-FAQ
What are the key factors to evaluate for ERFSF?
Eurofins Scientific SE (ERFSF) currently holds an AI score of 43/100, indicating low score. Key strength: Global presence with an extensive network of laboratories.. Primary risk to monitor: Potential: High debt-to-equity ratio could limit financial flexibility.. This is not financial advice.
How frequently does ERFSF data refresh on this page?
ERFSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ERFSF's recent stock price performance?
Recent price movement in Eurofins Scientific SE (ERFSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Global presence with an extensive network of laboratories.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ERFSF overvalued or undervalued right now?
Determining whether Eurofins Scientific SE (ERFSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ERFSF?
Before investing in Eurofins Scientific SE (ERFSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ERFSF to a portfolio?
Potential reasons to consider Eurofins Scientific SE (ERFSF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Global presence with an extensive network of laboratories.. Additionally: Diversified service offerings across multiple industries.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ERFSF?
Yes, most major brokerages offer fractional shares of Eurofins Scientific SE (ERFSF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ERFSF's earnings and financial reports?
Eurofins Scientific SE (ERFSF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ERFSF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- The information provided in this dossier is based on available data and analysis as of March 18, 2026. Market conditions and company performance may change over time.
- AI analysis is pending and may provide further insights into the company's performance and prospects.